

Effects of post-exercise sodium bicarbonate ingestion on acid-base balance recovery and time-toexhaustion running performance: a randomised crossover trial in recreational athletes

William H. Gurton<sup>1,3</sup>, Heather Z. Macrae<sup>1</sup>, Lewis A. Gough<sup>2</sup>, David G. King<sup>1</sup>

<sup>1</sup> Surrey Human Performance Institute, University of Surrey, Guildford, United Kingdom;

<sup>2</sup>Research Centre for Life and Sport Sciences (CLaSS), School of Health Sciences, Birmingham City

University, Birmingham, United Kingdom;

<sup>3</sup> Department of Sport, Exercise and Rehabilitation Sciences, Canterbury Christchurch University, Canterbury, United Kingdom.

**Corresponding author:** <sup>3</sup> Mr William H. Gurton, Department of Sport, Exercise and Rehabilitation Sciences, Canterbury Christchurch University, Canterbury, Kent, CT1 1QU, United Kingdom. <u>william.gurton@canterbury.ac.uk</u>

Other contact details: heather.macrae@btopenworld.com lewis.gough@bcu.ac.uk d.g.king@surrey.ac.uk

# 1 ABSTRACT

2 This study investigated the effect of post-exercise sodium bicarbonate (NaHCO<sub>3</sub>) ingestion on acid-3 base balance recovery and time-to-exhaustion (TTE) running performance. Eleven male runners 4 (stature,  $1.80 \pm 0.05$  m; body mass,  $74.4 \pm 6.5$  kg; maximal oxygen consumption,  $51.7 \pm 5.4$  ml.kg<sup>-</sup> 5 <sup>1</sup>.min<sup>-1</sup>) participated in this randomised, single-blind, counterbalanced and crossover design study. 6 Maximal running velocity (v-VO<sub>2max</sub>) was identified from a graded exercise test. During experimental</sub>7 trials, participants repeated 100% v-VO<sub>2max</sub> TTE protocols (TTE1, TTE2) separated by 40 min 8 following the ingestion of either 0.3 g.kg<sup>-1</sup> BM NaHCO<sub>3</sub> (SB) or 0.03 g.kg<sup>-1</sup> BM sodium chloride (PLA) 9 at the start of TTE1 recovery. Acid-base balance (blood pH and bicarbonate, HCO<sub>3</sub><sup>-</sup>) data were studied 10 at baseline, post-TTE1, after 35 min recovery and post-TTE2. Blood pH and [HCO<sub>3</sub><sup>-</sup>] were unchanged 11 at 35 min recovery (p > 0.05), but [HCO<sub>3</sub><sup>-</sup>] was elevated post-TTE2 for SB vs. PLA (+2.6 mmol.1<sup>-1</sup>; p12 = 0.005; g = 0.99). No significant differences were observed for TTE2 performance (p > 0.05), although a moderate effect size was present for SB vs. PLA (+14.3 s; g = 0.56). Post-exercise NaHCO<sub>3</sub> ingestion 13 14 is not an effective strategy for accelerating the restoration of acid-base balance or improving subsequent 15 TTE performance when limited recovery is available.

16

17 **Key Words:** buffering; alkalosis; glycolytic activation; ergogenic aid; exercise capacity; nutrition.

18

# 19 BULLET POINTS

- Post-exercise sodium bicarbonate ingestion did not accelerate the restoration of blood pH or
   bicarbonate after 35 minutes
- Performance enhancing effects of sodium bicarbonate ingestion may display a high degree of
   inter-individual variation
- Small-to-moderate changes in performance were likely due to greater up-regulation of 25 glycolytic activation during exercise
- 26

27

#### 28 INTRODUCTION

Repeated high-intensity training sessions and events require athletes to be able to maximally exert 29 30 themselves with often only limited recovery between exercise bouts (Barnett, 2006). The considerable 31 reliance on the ATP-PCr and glycolytic energetic systems results in the rapid accumulation of 32 biochemical metabolites such as inorganic phosphate, hydrogen cations  $(H^+)$  and lactate within 33 contracting muscle (Allen et al., 2008). Naturally occurring extracellular buffering mechanisms (e.g., 34 blood bicarbonate,  $HCO_3$ ) act to remove these H<sup>+</sup> from the muscle cytosol (Sahlin, 2014), however the 35 production of H<sup>+</sup> overwhelms the rate of neutralisation reactions, contributing towards reduced 36 intramuscular pH (Allen et al., 2008). These metabolically derived disruptions to acid-base balance (i.e., 37 equilibrium between acidity and alkalinity of bodily fluids) have been linked to greater peripheral 38 fatigue via the inhibition of glycolytic flux (Messonnier et al., 2007), disruption of calcium ion cross-39 bridge formation (Fitts, 2016) and reduced muscle excitability (Sostaric et al., 2006). Extracellular 40 buffering aids such as sodium bicarbonate (NaHCO<sub>3</sub>) that protect against disturbances to acid-base 41 balance homeostasis could therefore prove beneficial to athletes performing repeated bouts of maximal 42 effort that are likely to exacerbate metabolic perturbation.

43 Pre-exercise ingestion of 0.3 g.kg<sup>-1</sup> BM NaHCO<sub>3</sub> enhances extracellular buffering capacity by 44 eliciting a metabolic alkalosis (i.e., increased blood [HCO<sub>3</sub><sup>-</sup>] of ~5-7 mmol.l<sup>-1</sup>) that allows for greater 45 H<sup>+</sup> efflux from the muscle (Messonnier et al., 2007), which may result in moderate ergogenic benefits 46 during high-intensity exercise (see review, Hadzic et al., 2019). This nutritional strategy also accelerates 47 the restoration of acid-base balance homeostasis within ~40 mins (Pruscino et al., 2008; Gough et al., 2019a), but it is unclear whether the heightened  $HCO_3^-$  buffering response extends to subsequent athletic 48 49 performance (i.e., for athletes competing in multiple exercise events). Authors investigating the effect 50 of pre-exercise NaHCO<sub>3</sub> ingestion on repeated bout performance reported minimal ergogenic benefits 51 during wingate protocols (3x30 s; 15 min recovery) and swimming time-trials (2x200 m; 30 min recovery) (Zabala et al., 2011; Pruscino et al., 2008). It is expected that pre-exercise ingestion resulted 52 in the enhanced HCO<sub>3</sub><sup>-</sup> buffering capacity being completely utilised within the preliminary bout (i.e., 53 from protecting against severe acid-base balance disturbances), which would explain blunted 54 55 performance benefits during subsequent exercise bouts.

56 One relatively novel strategy that accounts for this concern is post-exercise NaHCO<sub>3</sub> ingestion, ensuring that a greater alkalotic response is present during recovery and subsequent exercise bouts. 57 58 Previous studies have demonstrated that NaHCO<sub>3</sub> ingested either immediately post-exercise or 30 min 59 after a fatiguing bout elevates blood pH (~0.10 units) and [HCO<sub>3</sub><sup>-</sup>] (~7-8 mmol.l<sup>-1</sup>) following a 75-90 60 min recovery period (Gough et al., 2017; Gough et al., 2019), which subsequently improved time-to-61 exhaustion (TTE) running (+70 s; p = 0.084) and cycling (+35 s; p = 0.007). Since the authors opted 62 for relatively long recovery windows, it was noted that blood pH and [HCO<sub>3</sub><sup>-</sup>] had not only recovered 63 prior to subsequent exercise, but instead reflected a state of pre-exercise metabolic alkalosis following NaHCO<sub>3</sub> ingestion (~7.48 units, ~32 mmol.l<sup>-1</sup>). Consequently, the ergogenic responses reported may 64 65 have represented the well-established pre-exercise application of NaHCO<sub>3</sub> ingestion. It is therefore 66 considered more appropriate to investigate the potential ergogenic effect of post-exercise NaHCO<sub>3</sub> 67 when ingested during a shorter recovery period between two exercise bouts.

68 Performance enhancing effects following NaHCO<sub>3</sub> are not exclusively attributed to substantial 69 changes in blood pH and [HCO<sub>3</sub><sup>-</sup>] response (Siegler et al., 2016). This alkalotic state may also increase 70 glycolytic activation by preventing the allosteric inhibition of enzymes such as glycogen phosphorlyase 71 and phosphofructokinase (Messonnier et al., 2007). Pre-exercise NaHCO<sub>3</sub> ingestion has been 72 demonstrated to augment glycolytic flux during high-intensity exercise protocols (da Silva et al., 2019; 73 Gurton et al., 2020). The effect of a post-exercise NaHCO<sub>3</sub> supplementation strategy on energy system 74 contribution during subsequent exercise remains underexplored, although authors have suggested 75 enhanced glycolytic flux via elevated post-exercise blood lactate (BLa<sup>-</sup>) concentration after a 75-90 min 76 recovery (Gough et al., 2017b; Gough et al., 2019b). It is conceivable that some athletes will have less 77 time to recover between high-intensity exercise bouts, therefore research should examine whether 78 NaHCO<sub>3</sub> ingested at the start of a shorter recovery period is still able to alter energy demand and 79 contribution from the glycolytic and oxidative systems.

80 From an applied perspective, athletes might be particularly attracted to nutritional strategies 81 that maximise ergogenic benefits during a second competition bout (i.e., track running/cycling, heat 82 then final; regional tennis, first and second round match). In these instances, ingestion of NaHCO<sub>3</sub> 83 during a recovery period may prove more beneficial to subsequent performance. The purpose of this

- study was to investigate the effect of post-exercise NaHCO<sub>3</sub> ingestion on the recovery of acid-base
  balance (blood pH, [HCO<sub>3</sub><sup>-</sup>], base excess) within 35 mins and subsequent TTE running performance.
- 86

## 87 MATERIALS AND METHODS

#### 88 **Experimental approach to the problem**

A block randomised, across subjects single-blind, placebo-controlled, counterbalanced, crossover 89 90 experimental design was implemented for this study. Experimental trial order was allocated by the 91 principal investigator using an online randomised number generator (www.randomization.com) and 92 blinded from other members of the research team. Participants attended three separate laboratory visits 93 in a 3-h post-prandial state to perform a graded exercise test and two experimental trials (separated by 94 5-7 d). All testing was completed at Surrey Human Performance Institute at the same time of day to 95 minimise the confounding effects of circadian rhythms on exercise performance (Reilly, 1990). The 96 final speed completed during the graded exercise test was classified as maximal velocity (100% v-97 VO<sub>2max</sub>) and used to prescribe TTE speed. During experimental trials, participants repeated 100% v-VO<sub>2max</sub> TTE protocols separated by 40 mins following the ingestion of either NaHCO<sub>3</sub> (SB) or sodium 98 99 chloride (NaCl; PLA) at the start of recovery. Vigorous exercise and the consumption of alcohol were 100 prohibited for 24-h prior to visits. Participants were instructed to record nutritional intake for 72-h prior 101 to attending the first laboratory visit using food diaries, which were checked by the principal 102 investigator and returned to participants to replicate before each experimental trial. Online databases 103 were used by the research team to determine the composition and nutritional content of foods.

104

## 105 **Participants**

106 A priori power calculation ( $\beta = 0.8$ ;  $\alpha = 0.05$ ) using previous partial eta-squared effect size data ( $\eta_p^2$ ; 107 0.6) for post-exercise blood pH recovery (Gough et al., 2017a) revealed that a sample size of 10 would 108 allow detection of significant changes in blood pH (G\*Power 3, Heinrich Heine, Düsseldorf, Germany). 109 Eleven recreationally trained runners (stature:  $1.80 \pm 0.05$  m; body mass:  $74.4 \pm 6.5$  kg; age:  $31.0 \pm 9.7$ 100 years; maximal oxygen consumption:  $51.7 \pm 5.4$  ml.kg<sup>-1</sup>.min<sup>-1</sup>) were enrolled onto this study from a 100 local running club according to the CONSORT 2010 guidelines (**Figure 1**). All participants completed at least 60 min vigorous exercise per week, had no history of hypertension (>140/90 mmHg) or renal insufficiencies and had not ingested buffering agents within the previous 6 months. All study procedures were reviewed and approved prior to commencing research by the Faculty of Health and Medical Sciences ethics committee at the University of Surrey (1366-FHMS-18). Participants gave informed consent prior to participating in the study. Procedures were conducted in full accordance with the World Medical Association's Declaration of Helsinki.

118

## 119 [INSERT Figure 1 NEAR HERE]

120

### 121 **Procedures**

122 On the initial visit, baseline physiological measures were recorded (stature, body mass, blood pressure), 123 before participants performed a graded exercise test on a treadmill to determine 100% v-VO<sub>2max</sub> for TTE protocols. Gaseous exchange was collected using a breath-by-breath metabolic cart (Geratherm 124 Respiratory, Love Medical, Germany). After a 5 min warm-up at 6 km.h<sup>-1</sup> and 1% gradient, the speed 125 increased by 1 km.h<sup>-1</sup> every 1 min until volitional exhaustion was achieved (Price and Halabi, 2005). 126 127 This was deemed as the failure to maintain treadmill speed despite strong verbal encouragement. Heart 128 rate and rating of perceived exertion (RPE) were recorded at the end of each stage and volitional 129 exhaustion. Data were averaged over the peak 30 s for calculating VO<sub>2max</sub> (Beltz et al., 2016) and 100% 130 v-VO<sub>2max</sub> was classified as the final completed speed during the graded exercise test.

131 On arrival to the laboratory during experimental trial visits, participants completed visual 132 analog scales for gastrointestinal (GI) discomfort (0 mm = "no symptom at all"; 100 mm = "severest 133 symptom imaginable") to quantify perceived severity of flatulence, abdominal discomfort (AD), gut fullness (GF), bowel urgency rating (BUR) and diarrhoea (Gough et al., 2017a; Gurton et al., 2020). 134 135 Resting capillary blood samples (95 µl) were collected into end-to-end sodium-heparised capillary tubes (EKF Diagnostics GmbH, Germany) and analysed for acid-base balance (blood pH, [HCO<sub>3</sub>-], base 136 excess) using a handheld analyser (i-STAT, Abbott Point of Care, New Jersey). The i-STAT analyser 137 demonstrates excellent accuracy and precision for determination of blood pH and [HCO3-] after 138 139 maximal exercise (intraclass correlation coefficients, ICC; r = 0.88, 0.86) (Dascombe et al. 2007).

140 Additional 20 µl blood samples were analysed for [BLa<sup>-</sup>] using an automatic analyser (Biosen C-Line, 141 EKF Diagnostic GmbH, Germany) that displays excellent precision (coefficient of variation, CV: 142 <1.5%; EKF Diagnostics, 2017). Participants perceived readiness to exercise (PRE) was measured, 143 before completing the first running TTE protocol (TTE1) at 100% v-VO<sub>2max</sub> on the treadmill (1% 144 gradient). Breath-by-breath expired gaseous exchange and RPE were recorded throughout TTE 145 protocols. Capillary blood samples and visual analog scales were performed immediately post-TTE1, before participants consumed either 0.3 g.kg<sup>-1</sup> BM NaHCO<sub>3</sub> (SB) or 0.03 g.kg<sup>-1</sup> BM NaCl (PLA) after 146 147 5 min recovery. These doses were chosen to replicate experimental design from previous studies 148 examining the effect of either pre- or post-exercise NaHCO<sub>3</sub> ingestion on recovery (Pruscino et al., 149 2008; Gough et al., 2017b; Gough et al., 2019b). Experimental beverages were administered single-150 blind as a chilled solution of 400 ml water and 100 ml orange squash to ensure palatability and taste-151 matching (Lavender and Bird, 1989). Pilot testing revealed it was not possible to taste-match an equimolar 0.21 g.kg<sup>-1</sup> BM NaCl dose (i.e., equal Na<sup>+</sup> content between beverages). Participants 152 153 consumed beverages as fast as possible but were allocated a 5 min period if required (i.e., by 10 min 154 post-TTE1), before completing a supplement belief questionnaire to assess the single-blind design and 155 whether bias regarding the effect of  $NaHCO_3$  was transferred onto participants (Gough et al. 2017a). 156 Capillary blood samples and visual analogue scales were repeated following 35 min recovery (30 min 157 post-ingestion). Participants were asked for their PRE and performed the second TTE protocol (TTE2) 158 at 100% v-VO<sub>2max</sub> on the treadmill (40 min after TTE1). Additional blood samples were collected post-159 TTE2, while visual analogue scales were completed post-exercise and for a 24-h post-laboratory phase. 160 Composite scores for GI discomfort were calculated at each time point from the sum of symptom 161 severity (i.e., scored out of 500 mm). An overview of experimental procedure is displayed in Figure 2. 162

- 163 [INSERT Figure 2 NEAR HERE]
- 164

# 165 Estimated energy system contribution calculations

Absolute energy demand and contribution from the oxidative and glycolytic energetic systems were estimated during TTE running protocols via non-invasive techniques (Milioni et al., 2017; Brisola et 168 al., 2015). Oxidative phosphorylation (WAER) was calculated by subtracting resting oxygen consumption (i.e., the average VO<sub>2</sub> value during the final 30 s of baseline) from the area under the 169 170 oxygen consumption curve for TTE protocols (di Prampero and Ferretti, 1999). Area under the curve 171 was calculated using the trapezoidal method. This approach provides reliable and valid estimations for 172 WAER during high-intensity exercise (da Silva et al., 2019; Milioni et al., 2017). Glycolytic (W[LA]) was 173 calculated from delta blood lactate ( $\Delta BLa^{-}$ ) during TTE protocols, according to the assumption that a difference of 1 mmol.1<sup>-1</sup> of BLa<sup>-</sup> corresponded to 3 ml.kg<sup>-1</sup> BM of O<sub>2</sub> (Milioni et al., 2017; Brisola et 174 al., 2015; Gurton et al., 2020), by using the following equation:  $W_{[LA]} = \Delta BLa^2 \times 3 \times body$  mass (kg). 175 The caloric quotient of 20.92 kJ was used to convert between absolute energy demand (in L of  $O_2$ ) and 176 177 energy contribution (in kJ) for both energetic systems.

178

## 179 Statistical analysis

Normality and sphericity were assessed using Shapiro-Wilk and Mauchly tests, respectively. Any violations were corrected via Greenhouse Geisser adjustments. Reproducibility of pre-trial nutritional intake, TTE1 performance, perceived difficulty to exercise and initial acid-base balance perturbation were determined from ICC's and categorised as either poor ( $r \le 0.40$ ), fair (r = 0.40 - 0.59), good (r =

184 0.60 - 0.74) or excellent ( $r \ge 0.74$ ) (Atkinson and Nevill, 1998). Acid-base balance (primary outcome

185 measure) data were analysed using two-way (treatment x time) repeated measures ANOVA's, whereby interaction effects were presented as a p value and effect size  $(\eta_p^2)$  (Olejnik and Algina, 2003). 186 187 Significant interactions were explored further by performing one-way repeated measures ANOVA 188 across treatments at *a* priori defined time points (i.e., post-TTE2) using the bonferroni correction factor. 189 The assumption of normal distribution was violated for GI discomfort therefore Friedman's two-way 190 ANOVA's were conducted as non-parametric alternative. Post-hoc Wilcoxon matched pair signed rank 191 tests were performed when significance was observed (median and Z score reported). Fisher's exact 192 test was used to assess the efficacy of the single-blind design. Paired t-tests were conducted on TTE2 193 performance (secondary outcome measure) and perceived difficulty to exercise. The within-subject CV 194 for the TTE1 protocol was calculated as 4.9% and used to interpret individual responses for changes in

- 195 TTE2 performance. Between treatment effect sizes were calculated by dividing mean differences by
- 196 pooled SD, before applying Hedges g bias correction (Lakens, 2013). These were interpreted as trivial

197 (<0.20), small (0.20 – 0.49), moderate (0.50 – 0.79), or large ( $\geq 0.80$ ) (Cohen, 1988). Data are presented

as Mean  $\pm$  SD (unless otherwise stated) and 95% confidence intervals (CI) reported for between treatment statistical differences. Statistical significance was set at *p* < 0.05 and data were analysed using SPSS v26 (SPSS Inc., IBM, USA).

201

202 RESULTS

## 203 Pre-trial nutritional intake

Participants demonstrated an excellent degree of repeatability for pre-trial nutritional intake during SB and PLA trials for daily calories (r = 0.89, p = 0.001), carbohydrate (r = 0.87, p = 0.002), fat (r = 0.83, p = 0.005) and protein (r = 0.83, p = 0.014).

207

# 208 Acid-base balance status

209 Initial acid-base balance perturbation demonstrated an excellent level of reproducibility during SB and PLA trials for post-TTE1 blood pH (r = 0.94; p < 0.001), [HCO<sub>3</sub><sup>-</sup>] (r = 0.95; p < 0.001), base excess (r210 = 0.92; p < 0.001) and [BLa<sup>-</sup>] (r = 0.93; p < 0.001). Significant two-way interactions (treatment x time) 211 were observed for [HCO<sub>3</sub><sup>-</sup>] (p = 0.002;  $\eta_p^2 = 0.413$ ) and [BLa<sup>-</sup>] (p = 0.023;  $\eta_p^2 = 0.269$ ), but not for blood 212 pH (p = 0.070;  $\eta_p^2 = 0.227$ ) or base excess (p = 0.242;  $\eta_p^2 = 0.141$ ). Acid-base balance status was 213 unchanged at 35 min recovery (p > 0.05). Exploratory analysis on a small sub-set (n = 6) of blood pH 214 and [HCO<sub>3</sub><sup>-</sup>] data at 40 min recovery (i.e., immediately pre-TTE2; not an *a* priori defined time point) 215 216 revealed a larger magnitude of effect for SB vs. PLA (+0.03 units; +3.9 mmol.1<sup>-1</sup>). Post-TTE2 [HCO<sub>3</sub><sup>-</sup>] was significantly elevated for SB vs. PLA (p = 0.005) and displayed a large effect size (+2.6 mmol.l<sup>-1</sup>; 217 CI: 1.0, 4.2; g = 0.99). Peak [BLa<sup>-</sup>] following TTE2 was significantly higher for SB vs. PLA (p = 0.015) 218 and displayed a large effect size (+1.4 mmol.1<sup>-1</sup>; CI: 0.3, 2.5; g = 0.82). Mean  $\pm$  SD values for changes 219 220 in acid-base balance status from baseline to post-TTE2 are displayed in Figure 3 (A-D).

221

222 [INSERT Figure 3 (A-D) NEAR HERE]

223

#### 224 Time-to-exhaustion running performance

Performance during TTE1 demonstrated an excellent degree of repeatability for SB and PLA trials (r = 225 226 0.95; p < 0.005; within-subject CV = 4.9%). No significant differences were observed for TTE2 performance (+14.3 s; p = 0.071), although a moderate effect size was present for SB vs. PLA (+9.7%; 227 228 g = 0.56). There was a large degree of individual variability for TTE2 performance, whereby mean 229 differences for SB vs. PLA ranged from -16.8 s (-14.2%) to +61.2 s (+37.1%). In total, six out of eleven participants reported improvements in TTE2 performance above the 4.9% test-retest variability. Sub-230 231 analysis for these six 'responders' revealed a significant increase of +31.2 s for TTE2 performance 232 following SB compared to PLA (+21.1 %; p = 0.007; g = 1.65). Mean values and individual differences 233 for TTE2 performance are displayed in Figure 4.

234

### 235 [INSERT Figure 4 NEAR HERE]

236

# 237 Estimated energy system contribution

238 Mean  $\pm$  SD values for energy demand (in L of O<sub>2</sub>) and contribution (kJ) from oxidative and glycolytic 239 energetic systems are presented in Table 1. Excellent reproducibility was observed between SB and 240 PLA trials for energy contribution from  $W_{AER}$  (r = 0.96; p < 0.001) and  $W_{[LA]}$  (r = 0.92; p < 0.001) 241 during TTE1. Energy contribution from W<sub>[LA]</sub> was significantly increased during TTE2 for SB vs. PLA (p = 0.032) and displayed a moderate effect size (+6.84 kJ; CI: 0.7, 13.0; g = 0.69). In total, ten out of 242 eleven participants reported greater W<sub>[LA]</sub> contribution following SB vs. PLA. No significant differences 243 were observed for energy contribution from  $W_{AER}$  during TTE2 (p > 0.05), although a small effect size 244 245 was present for SB vs. PLA (+11.20 kJ; g = 0.48). 246

247 [INSERT Table 1 NEAR HERE]

248

## 249 Perceived difficulty of exercise

Participants achieved a similar level of volitional exhaustion during TTE1 for SB and PLA trials as good reproducibility was reported for peak RPE (r = 0.66; p = 0.049). No differences were observed between SB and PLA for peak RPE during TTE2 (p > 0.05). No significant differences were reported across treatments for PRE prior to TTE2 (p > 0.05), although a small effect size was present for SB vs. PLA (+0.36 units; g = 0.26).

255

# 256 Perceptual responses to experimental beverages

Four participants identified SB, six were unsure on treatments, whilst one incorrectly identified SB as PLA. Treatments were therefore considered successfully single-blinded and taste-matched (Fisher's exact test, p = 1.000) and only a single participant directly suggested a poor taste.

260 In total, ten out of eleven participants experienced some GI discomfort for the SB trial (timing 261 and severity of peak symptom for each participant displayed in Table 2). Composite scores for GI 262 discomfort revealed no symptoms at baseline, but symptom severity was mildly exacerbated for SB vs. PLA at 35 min recovery (Mdn: 11 mm vs. 10 mm) and post-TTE2 (Mdn: 11 mm vs. 9 mm). No 263 264 significant treatment effects were present at any time point for AD or GF (p > 0.05). No significant 265 treatment effects were observed at either 35 min recovery or post-TTE2 for flatulence, BUR and 266 diarrhoea (all p > 0.05). Ratings of GI discomfort were significantly exacerbated for SB vs. PLA during 267 the 24-h post-laboratory phase for flatulence (Mdn: 10 mm vs. 0 mm; Z = 2.366; p = 0.018), BUR (20 268 mm vs. 0 mm; Z = 2.547; p = 0.011) and diarrhoea (17 mm vs. 0 mm; Z = 2.197; p = 0.028). Out of the 269 five participants that failed to improve TTE2 performance for SB vs. PLA, only one directly reported 270 an ergolytic effect of GI discomfort.

271

# 272 [INSERT Table 2 NEAR HERE]

273

### 274 **DISCUSSION**

This was the first study to investigate the effect of post-exercise NaHCO<sub>3</sub> ingestion on blood pH and [ $HCO_3^{-}$ ] recovery after 35 min and subsequent TTE running performance. No changes in acid-base balance status were reported for SB vs. PLA after the 35 min recovery period, however both [ $HCO_3^{-}$ ] and [BLa<sup>-</sup>] were elevated post-TTE2. Post-exercise NaHCO<sub>3</sub> ingestion did not significantly improve
TTE2 performance, although a moderate effect size and a high degree of inter-individual variation was
observed. Glycolytic energy system contribution was moderately increased during TTE2 for SB vs.
PLA. Lastly, post-exercise NaHCO<sub>3</sub> ingestion resulted in moderate-to-severe GI symptoms after TTE2
and for the 24-h post-laboratory phase, therefore athletes should remain cautious when using this
strategy to improve performance.

284 The novel finding from this study was that NaHCO<sub>3</sub> ingested after a fatiguing exercise bout 285 failed to accelerate the recovery of blood pH, [HCO<sub>3</sub><sup>-</sup>] and base excess to 'neutral' levels within 35 min when compared to PLA. These results contrast findings from pre-exercise ingestion studies suggesting 286 287 that NaHCO<sub>3</sub> accelerated the restoration of acid-base balance homeostasis within 30-40 min (Pruscino 288 et al., 2008; Gough et al., 2019a). This discrepancy is most likely explained by the pre-exercise ingestion 289 strategy previously employed, since this would have resulted in the enhanced buffering response being utilised during initial exercise (i.e., protecting against severe acid-base balance disturbances), in turn 290 291 allowing for blood pH and  $[HCO_3]$  to recover to baseline status 'faster'. Indeed, Gough et al. (2017b) 292 reported that NaHCO<sub>3</sub> administered following TTE cycling improved acid-base balance within 90 min 293 compared to a placebo (blood pH,  $\sim 0.10$  units; [HCO<sub>3</sub><sup>-</sup>],  $\sim 7.0$  mmol.l<sup>-1</sup>). Nonetheless, as the authors 294 waited until ~30 min post-exercise to administer NaHCO<sub>3</sub>, it was observed that blood pH and [HCO<sub>3</sub><sup>-</sup>] 295 had already naturally returned close to baseline (~7.42; ~25.0 mmol.1<sup>-1</sup>), therefore their results may 296 represent the widely regarded alkalotic effect of pre-exercise supplementation.

297 Our findings complement those from Gough et al. (2019b) demonstrating that post-exercise NaHCO<sub>3</sub> ingestion from a state of metabolic acidosis resulted in a greater [HCO<sub>3</sub>-] after 75 min recovery 298 299 (+8.6 mmol.l<sup>-1</sup>). The relatively unchanged acid-base balance status at 35 min recovery herein can be 300 attributed to a blunted extracellular buffering response since orally administered HCO<sub>3</sub><sup>-</sup> had likely not 301 been fully absorbed within the duodenum (Gough et al., 2017a). It is expected that substantial changes 302 in enhanced HCO<sub>3</sub><sup>-</sup> buffering only commenced during the second TTE protocol, which is demonstrated 303 by the elevated [HCO<sub>3</sub><sup>-</sup>] for post-TTE2 following SB, thus offering one possible explanation for the 304 moderate effect size reported for TTE2 performance. These findings suggest however that the ingestion

305 of NaHCO<sub>3</sub> immediately post-exercise is not an effective strategy for accelerating the restoration of 306 acid-base balance homeostasis when only a limited recovery period is available.

307 The performance enhancing effects of NaHCO<sub>3</sub> ingestion on TTE running were considerably 308 blunted when compared to previous post-exercise NaHCO<sub>3</sub> studies (Gough et al., 2017b; Gough et al., 309 2019b), instead more closely representing the equivocal benefits reported during repeated bout exercise 310 protocols (Zabala et al., 2011; Pruscino et al., 2008). The discrepancy between results is attributed to a 311 dampened extracellular buffering response, whereby all participants ended the recovery period in a 312 relatively 'neutral' acid-base balance status (i.e., opposed to a metabolic alkalosis from previous post-313 exercise studies). Despite the continual rise in  $[HCO_3]$  during the warm-up prior to TTE2 that was 314 demonstrated by our sub-set of data for 40 min recovery, it is unlikely that differences in [HCO<sub>3</sub>] for SB vs. PLA consistently achieved the 5.0-6.0 mmol.1<sup>-1</sup> minimal buffering threshold that has been 315 316 theorised to maximise potential performance benefits (Carr et al., 2011). These changes in TTE2 317 performance did however display a large degree of inter-individual variation, whereby a significant 318 'true' effect of NaHCO<sub>3</sub> was observed for the six participants (i.e., 'responders') that improved TTE2 319 duration above the 4.9% within-subject CV for the TTE protocol. Considering that large variability in 320 performance responses following NaHCO<sub>3</sub> ingestion is common (Saunders et al., 2014), likely due to 321 between participant differences in HCO3<sup>-</sup> absorption kinetics (Gough et al. 2017a), it is recommended 322 that athletes first trial the supplement within training regimes, before then applying to a competitive 323 'real-world' situation if positive results are obtained. Nonetheless, as three of these 'responders' 324 identified SB (from a breaking of study blinding due to GI symptoms) and reported higher PRE (~2 325 units) prior to TTE2, it is also possible that improvements were partially accounted to an 'expectancy 326 of ergogenicity' following NaHCO<sub>3</sub> ingestion (Higgins and Shaabir, 2016). Additional work should 327 now investigate the inter-individual variation of performance enhancing effects following post-exercise NaHCO<sub>3</sub> ingestion on more robust time-trial protocols that are less likely to be influenced by 328 329 psychological bias.

330 Post-exercise NaHCO<sub>3</sub> ingestion elevated  $W_{[LA]}$  energy contribution during subsequent 331 exercise, which agrees with previous pre-exercise ingestion findings (Gurton et al., 2020; da Silva et 332 al., 2019) and offers additional mechanistical insight to explain changes in TTE performance. Despite 333 the limited recovery period, an acute NaHCO<sub>3</sub> dose induced a sufficient change in alkalotic state to 334 augment total glycolytic flux during TTE2, which was likely caused by up-regulated lactate-H<sup>+</sup> co-335 transport from intramuscular environments via the monocarboxylate transporter (Messonnier et al., 2007). The elevated post-TTE2 [BLa] indirectly demonstrates increased activation of the glycolytic 336 337 energetic system following NaHCO<sub>3</sub> ingestion, although the magnitude of increase was lower than from previous studies (Gough et al., 2017b; Gough et al., 2019b). One explanation for this discrepancy relates 338 339 to the diminished extracellular buffering response as  $[HCO_3^-]$  was only ~3-4 mmol.1<sup>-1</sup> higher at the start 340 of TTE2 for SB vs. PLA, whereas Gough et al. (2017b) induced a substantial metabolic alkalosis prior to the second exercise bout ([HCO<sub>3</sub><sup>-</sup>]: ~7 mmol.l<sup>-1</sup> higher), resulting in a greater number of H<sup>+</sup> that could 341 342 be neutralised. Based on the 1:1 stoichiometry of the  $HCO_3^-$  and  $H^+$  reaction, and assuming that total 343 blood volume was ~5 L, then SB from this current study would have only neutralised an additional ~15 344 mmol.1<sup>-1</sup> of H<sup>+</sup> compared to PLA (opposed to ~30 mmol.1<sup>-1</sup> from Gough et al., 2017b), therefore 345 providing justification for our dampened up-regulation of glycolytic contribution. It is important to note 346 though, our results may partially reflect greater lactate efflux from muscles, instead of an increased 347 glycolytic flux (da Silva et al., 2019). Considering that participants also reported small, unexpected 348 increases for W<sub>AER</sub> during TTE2, which were partly attributed to the greater total work performed for 349 SB vs. PLA (i.e., increased running distance), it is possible that we slightly overestimated the 'true' 350 effect of NaHCO<sub>3</sub> on energy system contribution. Future research should investigate whether NaHCO<sub>3</sub> 351 ingested within recovery directly up-regulates glycolytic flux (i.e., from invasive muscle biopsies 352 techniques) during subsequent controlled work-rate/duration exercise protocols.

353 Moderate-to-severe GI symptoms following the dissociation of NaHCO3 within gastric acid 354 have been widely documented (Cameron et al., 2010; Carr et al., 2011). Our results demonstrated mildly 355 exacerbated GI discomfort for SB at 35 min recovery compared to baseline, which is in agreement to 356 one post-exercise ingestion study (Gough et al., 2017b), but not the other (Gough et al., 2019b). These disparities might be attributed to differences in assessment protocols (i.e., visual analogue scales vs. 11-357 point likert scales), or the established inter-individual variation for GI discomfort, whereby some 358 359 athletes report greater gastric tolerability to NaHCO<sub>3</sub> ingestion than others (Heibel et al., 2018). GI 360 discomfort was moderately exacerbated for SB vs. PLA post-TTE2 (i.e., reflecting worse symptoms

361 during exercise), however only a single participant suggested these side-effects impacted TTE2 performance, therefore our results reaffirm that GI discomfort might not directly exhibit an ergolytic 362 effect (Higgins et al., 2013; Gough et al., 2018). One novel finding was that post-exercise NaHCO<sub>3</sub> 363 ingestion resulted in severe GI discomfort for the 24-h post-laboratory phase (i.e., n = 5, diarrhoea), in 364 365 theory proving detrimental to athletes during future training and competition. Athletes suffering from severe GI discomfort could opt for delivery strategies that bypass gastric side-effects, such as 366 367 administration via enteric-coated capsules which adequately reduce severity and occurrence of GI 368 symptoms (Hilton et al., 2020a), whilst still eliciting a sufficient, albeit delayed metabolic alkalosis (>6.0 mmol.l<sup>-1</sup>; peak response, 90-110 min) that improves exercise performance (Hilton et al., 2020b). 369 370 Additional work is required to elucidate the efficacy of enteric-coated NaHCO<sub>3</sub> capsules when only a 371 limited amount of time is available between exercise bouts.

372 There are some methodological limitations in the present study. Firstly, a single-blind study 373 design is considered sub-optimal for nutritional intervention research, however this was purely due to 374 logistical reasons (i.e., lack of research staff). Additional control measures were put in place such as the 375 standardisation of verbal encouragement during TTE protocols (e.g., "keep going" every 15 s) and the 376 use of a supplement belief questionnaire (Gough et al., 2017a) that for the most part indicated we 377 blinded NaHCO<sub>3</sub> from participants. Another limitation was our inability to directly quantify glycolytic 378 flux and contribution from the ATP-PCr energetic system. Due to the importance of measuring blood 379 pH and  $[HCO_3^-]$  immediately post-exercise, we were unable to identify a clear excess-post oxygen 380 consumption curve after TTE exercise, therefore ATP-PCr calculations were removed from analysis. 381 Lastly, the 35 min recovery was potentially too short for post-exercise NaHCO<sub>3</sub> ingestion to have a 382 substantial effect on acid-base balance recovery, although previously published data (Gough et al., 2017a) suggests that 0.3 g.kg<sup>-1</sup> BM NaHCO<sub>3</sub> increases [HCO<sub>3</sub><sup>-</sup>] by ~5.0 mmol.l<sup>-1</sup> within 40 min. This 383 384 length of recovery was chosen as it best reflects the time required for blood pH and  $[HCO_3^-]$  to naturally return close to baseline (Gough et al., 2017b; Pruscino et al., 2008), which allowed us to investigate the 385 effect of post-exercise NaHCO3 ingestion on the restoration of acid-base balance homeostasis and 386 387 whether this improved subsequent high-intensity performance.

388

#### 389 CONCLUSION

390 The ingestion of NaHCO<sub>3</sub> immediately after an initial fatiguing exercise bout is not an effective strategy 391 for accelerating the restoration of acid-base balance homeostasis (blood pH, HCO<sub>3</sub><sup>-</sup>, base excess) when 392 only a limited recovery period is present. This was attributed to a blunted extracellular buffering 393 response, most likely as orally administered HCO<sub>3</sub><sup>-</sup> had not been fully absorbed within the duodenum. 394 Post-exercise NaHCO<sub>3</sub> ingestion did not significantly improve TTE2 performance, although the 395 moderate effect size and high degree of variability advocate that coaches and practitioners administer NaHCO<sub>3</sub> on an individual basis. Small-to-moderate changes in TTE2 performance were likely due to 396 397 enhanced HCO<sub>3</sub><sup>-</sup> buffering and the up-regulation of glycolytic activation specifically during TTE2 398 exercise. NaHCO<sub>3</sub> ingestion resulted in severe post-exercise GI discomfort that may prove detrimental 399 to athletes during subsequent training bouts or competition events. Future research should investigate 400 the application of alternative NaHCO<sub>3</sub> administration strategies (e.g., enteric-coated capsules) on the recovery of acid-base balance, GI discomfort and repeated bout exercise performance. 401

402	Acknowledgments
403	The authors would like to thank all participants for their efforts during this study.
404	
405	Competing interests statement
406	The authors declare that there are no competing interests related to the nutritional supplement or
407	outcomes of the study.
408	
409	Contributors' statement
410	WG and DK designed the study. WG, HM and DK collected the data. WG performed data analysis and
411	interpretations. WG prepared the majority of manuscript, HM, LG and DK also contributed. All authors
412	reviewed the manuscript and provided feedback.
413	
414	Funding statement

#### REFERENCES

Allen, D.G., Lamb, G.D. and Westerblad, H. 2008. Skeletal muscle fatigue: cellular mechanisms. *Physiological Reviews*, 88(1), p. 287-332. doi:10.1152/physrev.00015.2007

Barnett, A. 2006. Using recovery modalities between training sessions in elite athletes. *Sports Medicine*, *36*(9), p. 781-796. doi:10.2165/00007256-200636090-00005

Beltz, N.M., Gibson, A.L., Janot, J.M., Kravitz, L., Mermier, C.M. and Dalleck, L.C. 2016. Graded exercise testing protocols for the determination of VO2max: historical perspectives, progress, and future considerations. *Journal of Sports Medicine*, 2016, p. 1-13. doi:10.1155/2016/3968393

Brisola, G.M.P., Miyagi, W.E., da Silva, H.S. and Zagatto, A.M., 2015. Sodium bicarbonate supplementation improved MAOD but is not correlated with 200-and 400-m running performances: a double-blind, crossover, and placebo-controlled study. *Applied Physiology, Nutrition, and Metabolism*, 40(9), p. 931-937. doi:10.1139/apnm-2015-0036

Cameron, S.L., McLay-Cooke, R.T., Brown, R.C., Gray, A.R. and Fairbairn, K.A. 2010. Increased blood pH but not performance with sodium bicarbonate supplementation in elite rugby union players. *International Journal of Sport Nutrition and Exercise Metabolism*, 20(4), p. 307-321. doi:10.1123/ijsnem.20.4.307

Carr, A.J., Slater, G.J., Gore, C.J., Dawson, B. and Burke, L.M. (2011b). Effect of sodium bicarbonate on [HCO3–], pH, and gastrointestinal symptoms. *International Journal of Sport Nutrition and Exercise Metabolism*. *21*(3), p. 189-194. doi:10.1123/ijsnem.21.3.189

Cohen, J. (1988). Statistical power analysis for the behavioral sciences (2nd edition, p. 567). New Jersey: Laurence Erlbaum Associates, Publishers, Hillsdal.

Dascombe, B. J., Reaburn, P. R. J., Sirotic, A. C. and Coutts, A. J. 2007. The reliability of the i-STAT clinical portable analyser. *Journal of Science and Medicine in Sport*, *10*(3), p. 135-140. doi:10.1016/j.jsams.2006.05.023

da Silva, R.P., de Oliveira, L.F., Saunders, B., de Andrade Kratz, C., de Salles Painelli, V., da Eira Silva, V. and Artioli, G.G. 2019. Effects of  $\beta$ -alanine and sodium bicarbonate supplementation on the estimated energy system contribution during high-intensity intermittent exercise. *Amino Acids*, *51*(1), p. 83-96. doi:10.1007/s00726-018-2643-2

di Prampero, P.E. and Ferretti, G. 1990. Factors limiting maximal oxygen consumption in humans. *Respiration Physiology*, *80*(2-3), p. 113-128. doi:10.1016/0034-5687(90)90075-A

Fitts, R. 2016. The role of acidosis in fatigue: pro perspective. *Medicine & Science in Sports & Exercise*, 48(11), p. 2335-2338. doi:10.1249/MSS.00000000001043

Gough, L.A., Deb, S.K., Brown, D., Sparks, S.A. and McNaughton, L.R. 2019a. The effects of sodium bicarbonate ingestion on cycling performance and acid base balance recovery in acute normobaric hypoxia. *Journal of Sports Sciences*, *37*(13), p. 1-8. doi:10.1080/02640414.2019.1568173

Gough, L.A., Rimmer, S., Sparks, A.S., McNaughton, L.R. and Higgins, M.F. 2019b. Post-exercise supplementation of sodium bicarbonate improves acid base balance recovery and subsequent high-intensity boxing specific performance. *Frontiers in Nutrition*, *6*(155). doi:10.3389/fnut.2019.00155

Gough, L.A., Deb, S.K., Sparks, S.A. and McNaughton, L.R. 2018. Sodium bicarbonate improves 4 km time trial cycling performance when individualised to time to peak blood bicarbonate in trained male cyclists. *Journal of Sports Sciences*, *36*(15), p. 1705-1712. doi:10.1080/02640414.2017.1410875

Gough, L.A., Deb, S.K., Sparks, A.S. and McNaughton, L.R. 2017a. The reproducibility of blood acid base responses in male collegiate athletes following individualised doses of sodium bicarbonate: a randomised controlled crossover study. *Sports Medicine*, *47*(10), p. 2117-2127. doi:10.1007/s40279-017-0699-x

Gough, L.A., Rimmer, S., Osler, C.J. and Higgins, M.F. 2017b. Ingestion of sodium bicarbonate (NaHCO3) following a fatiguing bout of exercise accelerates post-exercise acid-base balance recovery and improves subsequent high-intensity cycling time to exhaustion. *International Journal of Sport Nutrition and Exercise Metabolism*, 27(5), p. 429-438. doi:10.1123/ijsnem.2017-0065

Gurton, W.H., Gough, L.A., Sparks, S.A., Faghy, M.A. and Reed, K.E. 2020. Sodium bicarbonate ingestion improves time-to-exhaustion cycling performance and alters estimated energy system contribution: a dose-response investigation. *Frontiers in Nutrition*, *7*(154). doi:10.3389/fnut.2020.00154

Heibel, A.B., Perim, P.H., Oliveira, L.F., McNaughton, L.R. and Saunders, B. 2018. Time to optimize supplementation: modifying factors influencing the individual responses to extracellular buffering agents. *Frontiers in Nutrition*, *5*(35), p. 1-12. doi:10.3389/fnut.2018.00035

Higgins, M.F., James, R.S. and Price, M.J. 2013. The effects of sodium bicarbonate (NaHCO3) ingestion on high intensity cycling capacity. *Journal of Sports Sciences*, *31*(9), p. 972-981. doi:10.1080/02640414.2012.758868

Higgins, M.F. and Shabir, A. 2016. Expectancy of erogenicity from sodium bicarbonate ingestion increases high-intensity cycling capacity. *Applied Physiology, Nutrition, and Metabolism, 41*(4), p. 405-410. doi:10.1139/apnm-2015-0523

Hilton, N.P., Leach, N.K., Craig, M.M., Sparks, S.A. and McNaughton, L.R. 2020a. Enteric-coated sodium bicarbonate attenuates gastrointestinal side-effects. *International Journal of Sport Nutrition and Exercise Metabolism*, *30*(1), p. 62-68. doi:10.1123/ijsnem.2019-0151

Hilton, N.P., Leach, N.K., Hilton, M.M., Sparks, S.A. and McNaughton, L.R. 2020b. Enteric-coated sodium bicarbonate supplementation improves high-intensity cycling performance in trained cyclists. *European Journal of Applied Physiology, 120* p. 1563-1573. 120:1563–1573 doi:10.1007/s00421-020-04387-5

Lakens, D. 2013. Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs. *Frontiers in Psychology*, *4*(863) p. 1-12. doi:10.3389/fpsyg.2013.00863

Lavender, G. and Bird, S.R. 1989. Effect of sodium bicarbonate ingestion upon repeated sprints. *British Journal of Sports Medicine*, 23(1), p. 41-45. doi:10.1136/bjsm.23.1.41

Messonnier, L., Kristensen, M., Juel, C., and Denis, C. 2007. Importance of pH regulation and lactate/H+ transport capacity for work production during supramaximal exercise in humans. *Journal of Applied Physiology*, *102*(5), p. 1936-1944. doi:10.1152/japplphysiol.00691.2006

Milioni, F., Zagatto, A.M., Barbieri, R.A., Andrade, V.L., dos Santos, J.W., Gobatto, C.A., da Silva, A.S., Santiago, P.R.P. and Papoti, M. 2017. Energy systems contribution in the running-based anaerobic sprint test. *International Journal of Sports Medicine*, 38(03), p. 226-232. doi:10.1055/s-0042-117722

Olejnik, S. and Algina, J. 2003. Generalized eta and omega squared statistics: measures of effect size for some common research designs. *Psychological Methods*, 8(4), p. 434-447. doi:10.1037/1082-989X.8.4.434

Price, M. and Halabi, K. 2005. The effects of work–rest duration on intermittent exercise and subsequent performance. *Journal of Sports Sciences*, *23*(8), p. 835-842. doi:10.1080/02640410400021971

Pruscino, C.L. Ross, M.L., Gregory, J.R., Savage, B. and Flanagan, T.R. 2008. Effects of sodium bicarbonate, caffeine, and their combination on repeated 200-m freestyle performance. *International Journal of Sport Nutrition and Exercise Metabolism*, *18*(2), p. 116-130. doi:10.1123/ijsnem.18.2.116

Reilly, T. 1990. Human circadian rhythms and exercise. *Critical reviews in biomedical engineering*, 18(3), p. 165-180. PMID: 2286092

Sahlin, K. 2014. Muscle energetics during explosive activities and potential effects of nutrition and training. *Sports Medicine*, *44*(2), p. 167-173. doi:10.1007/s40279-014-0256-9

Saunders, B., Sale, C., Harris, R.C. and Sunderland, C. 2014. Sodium bicarbonate and high-intensitycycling capacity: variability in responses. *International Journal of Sports Physiology and Performance*, 9(4), p. 627-632. doi:10.1123/IJSPP.2013-0295

Siegler, J.C., Marshall, P.W., Bishop, D., Shaw, G. and Green, S. 2016. Mechanistic insights into the efficacy of sodium bicarbonate supplementation to improve athletic performance. *Sports Medicine*, *2*(1), p. 41. doi:10.1186/s40798-016-0065-9

Sostaric, S.M., Skinner, S.L., Brown, M.J., Sangkabutra, T., Medved, I., Medley, T., Selig, S.E., Fairweather, I., Rutar, D. and McKenna, M.J., 2006. Alkalosis increases muscle K+ release, but lowers plasma [K+] and delays fatigue during dynamic forearm exercise. *The Journal of Physiology*, *570*(1), p. 185-205. doi:10.1113/jphysiol.2005.094615

Zabala, M., Peinado, A.B., Calderón, F.J., Sampedro, J., Castillo, M.J. and Benito, P.J. 2011. Bicarbonate ingestion has no ergogenic effect on consecutive all out sprint tests in BMX elite cyclists. *European Journal of Applied Physiology*, *111*(12), p. 3127-3134. doi:10.1007/s00421-011-1938-

# **Figure captions**

Figure 1 CONSORT 2010 reporting guidelines for research flowchart.

**Figure 2** Overview of study design and experimental procedures. Abbreviations: *v-VO2max*, maximal running velocity; *SB*, sodium bicarbonate; *PLA*, placebo; *GI*, gastrointestinal; *BLa*, blood lactate; *BG*, blood gas; *PRE*, perceived readiness to exercise; *TTE1/2*, time-to-exhaustion protocol one/two.

**Figure 3** (**A-D**) Mean  $\pm$  SD changes in acid-base balance status (**A**, blood bicarbonate; **B**, blood pH; **C**, base excess; **D**, blood lactate). Some error bars are removed for clarity. \* denotes significantly higher for SB vs. PLA (p < 0.05). Dashed horizontal lines represent baseline/normal acid-base balance status.

**Figure 4** Mean differences and inter-individual variation (dashed lines between data points) for subsequent time-to-exhausting running protocols.